ClinicalTrials.gg
RecruitingNCT06497894Updated Jan 13, 2026

No More Sleepless Nights in Perimenopause

A Phase 4 interventional study of Cognitive Behavioural Therapy for Insomnia (CBT-I) and Hormone Replacement Therapy (HRT) in Insomnia and Menopause, sponsored by Insel Gruppe AG, University Hospital Bern. Recruiting at 1 site in Switzerland. Open to female participants aged 45 Years to 69 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-13.

Sponsored by Insel Gruppe AG, University Hospital Bern · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
54
Allocation
Randomized
Ages
45 Years to 69 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 34 studies in Sleep Initiation and Maintenance Disorders with a site in Switzerland — 8 open to participants now, 9 under way, none of them phase 3. Sleep Initiation and Maintenance Disorders · Switzerland.

Planned enrollment
20th of 27
54 · median 68
Started
2026
the only one that year
Phase 4
3 of 34
1 open now
Registered
28th of 34
by date
Lead sponsor
4 of 34
Insel Gruppe AG, University Hospital Bern

Among the 34 studies in Sleep Initiation and Maintenance Disorders with a site in Switzerland, this one is the 20th largest by planned enrollment of the 27 interventional ones that give a count, is the only one that started in 2026, is one of 3 in phase 4, and was the 28th registered.

Sleep Initiation and Maintenance Disorders

2,738 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 735 are open to participants now.

Browse Sleep Initiation and Maintenance Disorders studies →

Open to participants now

8 of the 34 studies in Sleep Initiation and Maintenance Disorders with a site in Switzerland are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 394 Sleep Initiation and Maintenance Disorders studies recruiting now, 156 (40%) set no upper age limit and 208 (53%) stop at 75 or younger; 61 take children under 18; 112 take healthy volunteers.

This study: 45 Years to 69 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Sleep Initiation and Maintenance Disorders with a site in Switzerland, or all of them as a file.
02

Study summary

The goal of the clinical trial is to learn if Hormone Replacement Therapy (HRT) and Cognitive Behavioral Therapy (CBT-I) can treat insomnia in menopausal women. The main questions it aims to answer are:

  • Are HRT and CBT-I effective in reducing insomnia in menopausal women?
  • Are HRT and CBT-I comparable in terms of reducing insomnia severity in this population?

Researchers will compare HRT and CBT-I to an active control group, receiving sleep hygiene instructions.

Participants will:

  • Complete a screening and baseline assessment
  • Receive Hormone Replacement Therapy (as prescribed), Cognitive Behavioral Therapy (1/week), or sleep hygiene instructions (1/week) for 8 weeks.
  • Keep a daily diary (sleep e-diary), to assess sleep-quality.
  • Wear an electroencephalogram (EEG) during 6 nights (3 at baseline \& 3 post-intervention), to assess deep sleep cycles and waking episodes.
  • Receive a phone call for intervention compliance
  • Complete a post-intervention assessment.
03

Conditions studied

  • Insomnia
  • Menopause

Keywords

  • Perimenopause
  • Insomnia
  • Cognitive Behavioral Therapy
  • Hormone Replacement Therapy
04

Who can participate

Ages eligible
45 Years to 69 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Late menopausal transition according to Stages of Reproductive Aging criteria (STRAW+10)
  • Pittsburgh Sleep Quality Index (PSQI) score > 5
  • Insomnia Severity Index (ISI) score > 7
  • Somato-vegetative domain of the Menopause Rating Scale (MRS)-II ≥ 4 points
  • Willingness to use HRT for menopausal symptom reliefs

Exclusion criteria

Exclusion Criteria:

  • Other sleep-wake disorders according to , assessed with validated questionnaires (Sleep-Health Questionnaire, Epworth Sleepiness Scale (ESS))
  • Untreated hormonal disorder
  • Obesity ( ≥ 30)
  • Current psychotherapy
  • Current psychopharmacological therapy including regular sleep medication
  • History of unsuccessful CBT-I
  • Psychiatric illness
  • Substance abuse (≥ 7 cigarettes/day, no more than 2 standard WHO drinks per day, other drugs)
  • Shift work
  • Long-haul flights across different time zones in the past 3 months
  • Pregnancy and lactation
  • to HRT according to drug information (https://www.swissmedicinfo.ch/)
  • Inability to follow procedures or insufficient knowledge of project language
  • Inability to give consent
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
54 participants (estimated)

Study arms

  • Experimental
    Cognitive Behavioral Therapy for insomnia (CBT-I)

    Participants in this experimental arm will receive cognitive behavioral therapy specifically designed to treat insomnia (CBT-I). The therapy will be delivered over 8 weekly sessions, each lasting 60 minutes. The sessions will include techniques such as sleep restriction, stimulus control, cognitive restructuring, and relaxation training. The primary goal is to improve sleep quality and reduce the severity of insomnia.

    Behavioral: Cognitive Behavioural Therapy for Insomnia (CBT-I)

  • Active comparator
    Hormone Replacement Therapy (HRT)

    Participants in this experimental arm will receive hormone replacement therapy, specifically a combination of estrogen and progesterone over the course of 8 weeks. The therapy aims to alleviate menopausal symptoms, including insomnia, by addressing hormonal imbalances.

    Drug: Hormone Replacement Therapy (HRT)

  • Sham comparator
    Sleep Hygiene

    Participants in this sham comparator arm will receive sleep hygiene instructions. Instructions will be delivered over 8 weekly sessions. The instructions will provide general information about healthy sleep habits, such as food and drink choices, a regular sleep schedule, evening routine, etc. Although being widely used in daily clinical practice, sleep hygiene shows no significant effect as monotherapy in patients with an established insomnia. The sleep hygiene condition in this study is matched to CBT-I in frequency and intensity of contact.

    Behavioral: Sleep Hygiene

Interventions

  • BehavioralCognitive Behavioural Therapy for Insomnia (CBT-I)

    CBT-I is conducted in an individual setting according to the manual used in McCurry (1). Factors at the level of behavior, cognitions, and physiology that perpetuate sleep onset and sleep maintenance disorders are addressed. In addition, psychoeducation on sleep and sleep hygiene, stimulus control, sleep restriction, relaxation, structured worry time, cognitive restructuring, and relapse prevention are part of the training. Each session will include homework.

  • DrugHormone Replacement Therapy (HRT)

    Standard-dose continuously-combined bio-identical HRT containing transdermal estradiol 1.5 mg/d (= 2 strokes of Oestrogel® Dispenser) and oral micronized progesterone (= 1 capsule of Utrogestan® 200). This combination is the most popular HRT regimen, as it has a neutral effect on lipids, glucose, haemostasis. Participants will receive a conventional prescription for the 2 products that are covered by all health insurances in Switzerland.

  • BehavioralSleep Hygiene

    Sleep hygiene refers to healthy sleep habits, e.g. food and drink choices, a regular sleep schedule, evening routine. Although being widely used in daily practice, sleep hygiene shows no significant effect as monotherapy in patients with an established insomnia. The sleep hygiene condition in this study is matched to CBT-I in frequency and intensity of contact.

06

What researchers measure

Primary outcomes

  1. Reduction of Insomnia Severity

    Change from baseline in Insomnia Severity Index (ISI). The ISI is a seven-item questionnaire, asking respondents to rate the severity of sleep-related symptoms on 5-point Likert scales (Ranging between 0 = not applicable and 4 = very strong). Total values may range between 0 and 28, where 0 indicates no presence of sleep-related symptoms and 28 indicates very severe symptoms.

    Time frame: Week 10

Secondary outcomes

  1. Improvement in Climacteric Syndrome

    Change from baseline in Menopause Rating Scale (MRS-II) The MRS-II is an eleven-item questionnaire, asking respondents to rate the severity of climcteric syndrome-related symptoms on 5-point Likert scales (Ranging between 0 = not applicable and 4 = very strong). Total values may range between 0 and 44, where 0 indicates no presence of symptoms and 44 indicates very severe symptoms.

    Time frame: Week 10

  2. Changes in bio-functional age

    Change from baseline in biofunctional status (i.e. differences between chronological age and biofunctional age).

    Time frame: Week 10

  3. Changes in maladaptive sleep-related cognitions

    Change from baseline in Dysfunctional Attitudes and Beliefs about Sleep Scale (DBAS). The DBAS is a sixteen-item questionnaire, asking respondents to rate their attitudes/beliefs about sleep on 10-point numerical rating-scales (discrete intervals), ranging between 0 (I do not agree at all) and 10 (I agree completely). Total values may range between 0 and 160, where 0 indicates no presence of dysfunctional attitudes and 160 indicates very severe levels of maladaptive sleep-related cognitions.

    Time frame: Week 10

07

Study locations

1 of 1 sites recruiting
  • University Hospital of Bern, Department of Gynecological Endocrinology & Reproductive Medicine
    Bern, 3010, Switzerland
    Recruiting
    • Petra Stute, Prof. · Contact+41 31 632 1010
08

References and documents

Publications

  • Pavicic E, Stute P, Rudzik F, Urech A, Lozza-Fiacco S. No more sleepless nights in perimenopause-an open-label, randomized, parallel-group, active controlled intervention study in perimenopausal women with vasomotor symptoms and insomnia to investigate the efficacy of hormone replacement therapy and cognitive behavioral therapy for the treatment of insomnia: study protocol. Trials. 2025 Dec 30;27(1):94. doi: 10.1186/s13063-025-09366-9. PubMed 41462320 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Jul 2026, 6 months after the start.

Of 53 non-industry phase 4 interventional studies under Sleep Initiation and Maintenance Disorders, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 59. This study's planned 6 months is below that.

Counting every sponsor, half of 58 studies reached it within 28 months; a quarter within 17 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 4, 2024
First posted
Jul 12, 2024
StartActual
Jan 1, 2026
Primary completionEst.
Jul 1, 2026
CompletionEst.
Jan 30, 2027
Last update
Jan 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06497894
Responsible party
Sponsor
First posted
Jul 12, 2024
Start date
Jan 1, 2026
Primary completion
Jul 1, 2026 (estimated)
Completion
Jan 30, 2027 (estimated)
Last update
Jan 13, 2026

Study contacts

Petra Stute, Prof.
Contact
petra.stute@insel.ch
+41 31 632 1010
Petra Stute, Prof.
principal investigator · University Hospital of Bern, Department of Gynecological Endocrinology & Reproductive Medicine

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion